{"classes":[{"categories":[{"measurements":[{"comment":"There were an insufficient number of participants with SRE events and no analysis was conducted.","groupId":"OG000","value":"NA"},{"comment":"There were an insufficient number of participants with SRE events and no analysis was conducted.","groupId":"OG001","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"175"}],"units":"Participants"}],"description":"Time from randomization to the date of the first occurrence of a symptomatic SRE (clinical need for radiotherapy or surgery to bone).","groups":[{"description":"Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.\n\nDexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.","id":"OG000","title":"Lenalidomide Plus Dexamethasone"},{"description":"Placebo PO daily on Days 1 to 28 of each 28 day cycle.\n\nDexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD for Days 1-4 every 28 days.","id":"OG001","title":"Placebo Plus Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Analysis not performed due to an insufficient number of participants with SRE","reportingStatus":"POSTED","timeFrame":"Up to unblinding data cut off of 03 August 2005; up to 24 months","title":"Time to First Symptomatic Skeletal-related Event (SRE) (Clinical Need for Radiation or Surgery to Bone)","type":"SECONDARY","unitOfMeasure":"participants"}